Repligen (NASDAQ: RGEN) reported Q3 EPS of $0.08, in-line with the analyst estimate of $0.08. Revenue for the quarter came in at $24.7 million versus the consensus estimate of $24.39 million.

GUIDANCE:

Repligen sees FY2016 EPS of $0.42-$0.48, versus the consensus of $0.44. Repligen sees FY2016 revenue of $102-105 million, versus the consensus of $104.0 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.